Joint (JYNT) Competitors $11.35 -0.01 (-0.09%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$11.36 +0.01 (+0.04%) As of 02/21/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends JYNT vs. AACT, ORC, TINV, GAMI, CTO, INV, FPI, VINP, APPS, and CHCTShould you be buying Joint stock or one of its competitors? The main competitors of Joint include Ares Acquisition Co. II (AACT), Orchid Island Capital (ORC), Tiga Acquisition (TINV), GAMCO Investors (GAMI), CTO Realty Growth (CTO), Innventure (INV), Farmland Partners (FPI), Vinci Partners Investments (VINP), Digital Turbine (APPS), and Community Healthcare Trust (CHCT). These companies are all part of the "trading" industry. Joint vs. Ares Acquisition Co. II Orchid Island Capital Tiga Acquisition GAMCO Investors CTO Realty Growth Innventure Farmland Partners Vinci Partners Investments Digital Turbine Community Healthcare Trust Joint (NASDAQ:JYNT) and Ares Acquisition Co. II (NYSE:AACT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends. Do analysts rate JYNT or AACT? Joint currently has a consensus target price of $17.50, indicating a potential upside of 54.19%. Given Joint's stronger consensus rating and higher possible upside, analysts plainly believe Joint is more favorable than Ares Acquisition Co. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ares Acquisition Co. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is JYNT or AACT more profitable? Ares Acquisition Co. II has a net margin of 0.00% compared to Joint's net margin of -13.95%. Joint's return on equity of 8.24% beat Ares Acquisition Co. II's return on equity.Company Net Margins Return on Equity Return on Assets Joint-13.95% 8.24% 2.33% Ares Acquisition Co. II N/A -128.65%5.02% Which has higher valuation & earnings, JYNT or AACT? Ares Acquisition Co. II has lower revenue, but higher earnings than Joint. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJoint$117.70M1.44-$9.75M-$1.14-9.96Ares Acquisition Co. IIN/AN/A$16.92MN/AN/A Does the MarketBeat Community believe in JYNT or AACT? Joint received 282 more outperform votes than Ares Acquisition Co. II when rated by MarketBeat users. CompanyUnderperformOutperformJointOutperform Votes28262.53% Underperform Votes16937.47% Ares Acquisition Co. IIN/AN/A Do institutionals and insiders believe in JYNT or AACT? 76.9% of Joint shares are owned by institutional investors. Comparatively, 72.9% of Ares Acquisition Co. II shares are owned by institutional investors. 30.2% of Joint shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to JYNT or AACT? In the previous week, Joint had 4 more articles in the media than Ares Acquisition Co. II. MarketBeat recorded 6 mentions for Joint and 2 mentions for Ares Acquisition Co. II. Ares Acquisition Co. II's average media sentiment score of 1.49 beat Joint's score of 0.98 indicating that Ares Acquisition Co. II is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Joint 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ares Acquisition Co. II 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryJoint beats Ares Acquisition Co. II on 9 of the 13 factors compared between the two stocks. Get Joint News Delivered to You Automatically Sign up to receive the latest news and ratings for JYNT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JYNT vs. The Competition Export to ExcelMetricJointPatent owners & lessors IndustryMedical SectorNASDAQ ExchangeMarket Cap$170.02M$1.05B$5.77B$8.98BDividend YieldN/A7.12%4.78%3.85%P/E Ratio-9.966.1626.4618.82Price / Sales1.44296.68453.2580.30Price / Cash15.7712.7344.0437.47Price / Book6.763.177.634.64Net Income-$9.75M$7.52M$3.18B$245.69M7 Day Performance-1.56%-4.95%-1.91%-2.66%1 Month Performance2.16%6.76%-0.19%-2.15%1 Year Performance12.82%14.50%16.70%12.90% Joint Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JYNTJoint4.0274 of 5 stars$11.35-0.1%$17.50+54.2%+12.8%$170.02M$117.70M-9.96320News CoverageAACTAres Acquisition Co. IIN/A$11.04+0.1%N/A+4.9%$690MN/A0.00N/ANews CoveragePositive NewsORCOrchid Island Capital4.1973 of 5 stars$8.33+0.5%$9.50+14.1%+6.5%$664.75M$54.41M13.882,018Positive NewsTINVTiga AcquisitionN/A$18.13+0.2%N/A+112.2%$625.49MN/A0.00N/AHigh Trading VolumeGAMIGAMCO InvestorsN/A$24.92+0.6%N/A+31.2%$603.56M$231.40M9.44170Gap DownCTOCTO Realty Growth3.7248 of 5 stars$19.99-0.1%$21.00+5.1%+15.3%$599.15M$109.12M33.8730Earnings ReportDividend AnnouncementAnalyst UpgradeNews CoveragePositive NewsGap DownINVInnventureN/A$12.05-4.1%$16.00+32.8%N/A$597.08MN/A0.00N/APositive NewsFPIFarmland Partners1.7267 of 5 stars$11.83+0.2%N/A+11.1%$569.61M$57.47M42.2330Earnings ReportDividend AnnouncementAnalyst DowngradeNews CoverageVINPVinci Partners Investments3.9926 of 5 stars$10.52+0.4%$13.50+28.3%-8.1%$565.77M$91.03M16.97240Upcoming EarningsAPPSDigital Turbine3.0617 of 5 stars$5.38+9.8%$2.38-55.9%+23.3%$564.94M$483.58M-1.78840CHCTCommunity Healthcare Trust2.6575 of 5 stars$20.00+0.1%$21.25+6.3%-29.2%$564.80M$112.85M-222.2230Earnings ReportNews CoveragePositive News Related Companies and Tools Related Companies Ares Acquisition Co. II Competitors Orchid Island Capital Competitors Tiga Acquisition Competitors GAMCO Investors Competitors CTO Realty Growth Competitors Innventure Competitors Farmland Partners Competitors Vinci Partners Investments Competitors Digital Turbine Competitors Community Healthcare Trust Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:JYNT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Joint Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Joint With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
